TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04693858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Anxiety Learning Modules (CALM)
Description: CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Anxiety Learning Modules--Relaxation (CALM-R)
Description: CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
Study: NCT04819022

Intervention type: DEVICE
Intervention: Acute and post-acute
Description: These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.

Intervention type: DEVICE
Intervention: Chronic
Description: These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
Study: NCT03362814

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Danoprevir Placebo
Description: Danoprevir Placebo tablet administered orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ritonavir Placebo
Description: Ritonavir Placebo tablet administered orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin Placebo
Description: Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 5 tablets and ≥75kg = 6 tablets)
Study: NCT02470325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avidekel oil
Description: Avidekel cannabis oil 6:1 CBD:THC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Avidekel oil
Description: Enriched Avidekel cannabis oil 20:1 CBD:THC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Avidekel oil
Description: Enriched Avidekel cannabis oil 20:1 CBD:THC
Study: NCT03319004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: apply phase lag entropy sensor
Description: apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
Study: NCT03970941

Intervention type: OTHER
Intervention: Cost evaluation
Description: The cost for the hospital of the strategy of management will be evaluated.

Intervention type: OTHER
Intervention: Cost evaluation
Description: The cost for the hospital of the strategy of management will be evaluated.

Intervention type: OTHER
Intervention: Questionnaire
Description: The quality of life of patients will be measured.
Study: NCT03343834

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biological collection
Description: At D0:~* blood samples~* saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation
Study: NCT04137731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential Current Therapy
Description: IFC treatment after Total Knee Arthroplasty
Study: NCT03501095

Intervention type: DIAGNOSTIC_TEST
Intervention: Vocal analysis and Laryngostroboscopy
Description: Vocal analysis study the acoustic emission of the pneumo-phono-articulatory system, i.e. the vocal signal. Currently, digital technology instruments enable the processing and analysis of the verbal signal quickly and reliably, also offering graphical products and numerical data. Among the various existing software products for the study of the vocal signal, PRAAT is available. In practice, the vocal parameters are acquired in a non-invasive way with a microphone.~Laryngostroboscopy is one of the most widely used techniques for laryngeal clinical evaluation. This is a non-invasive endoscopic practice performed by means of a flexible fibroscope, which, through a pulsed light source, allows visualization of the chordal movement.
Study: NCT01401933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linifanib
Description: QD on Days 1 and 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: QD on Days 5-16
Study: NCT01388842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
Study: NCT01933906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101
Study: NCT04023877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: E2027 oral capsule.
Study: NCT01652391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)
Study: NCT00314366

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Therapy
Description: Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (plasma)
Description: Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
Study: NCT02549508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoCPAP with SensAwake On
Description: The comfort feature 'SensAwake' will be turned on

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoCPAP with SensAwake On
Description: The comfort feature 'SensAwake' will be turned on

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoCPAP with SensAwake Off
Description: The comfort feature 'SensAwake' will be turned off

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoCPAP with SensAwake Off
Description: The comfort feature 'SensAwake' will be turned off
Study: NCT03139890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat (HF-LC-LP) milkshake
Description: During this experimental day, men will receive a high-fat milkshake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (LF-HC-LP) milkshake
Description: During this experimental day, men will receive a high-carbohydrate milkshake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein (LF-LC-HP) milkshake
Description: During this experimental day, men will receive a high-protein milkshake
Study: NCT01261858

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kryptonite
Description: osteoconductive biologic bone cement to be applied upon sternal closure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kryptonite
Description: osteoconductive biologic bone cement to be applied upon sternal closure
Study: NCT03709537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Peer Workforce Support
Description: Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency.
Study: NCT04137731

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Interferential Current Therapy
Description: IFC treatment after Total Knee Arthroplasty
Study: NCT01897948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk-based beverage without DHA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk-based beverage with DHA at mid level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk-based beverage with DHA at high level
Study: NCT02675010

Intervention type: OTHER
Group type: OTHER
Intervention: ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
Description: ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
Study: NCT01491997

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind/Body Medicine Course 1
Description: The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind/Body Medicine Course 2
Description: The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
Study: NCT00432341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: 200 Units at Visit 1 (Day 1)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: 500 Units at Visit 1 (Day 1)
Study: NCT04383782

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expectancy Challenge
Description: Expectancy challenge intervention (see description in study arms).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancy Challenge + Behavioral Activation
Description: Expectancy challenge + behavioral activation interventions (see description in study arms)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Neutral reading condition (see description in study arms).
Study: NCT04819022

Intervention type: DEVICE
Intervention: Post-surgical
Description: These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
Study: NCT02173015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensatory step training
Description: The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
Study: NCT01249404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. injection on day 1 (single treatment cycle)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. injection on day 1 (single treatment cycle)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.M. injection on day 1 (single treatment cycle)
Study: NCT01856920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
Description: GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
Description: GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
Study: NCT00528294

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GRID radiotherapy
Description: GRID-radiotherapy followed by biological imaging guided IMRT
Study: NCT02653131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-4 inhibitor
Study: NCT03011931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
Study: NCT04601389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab (JSC GENERIUM, the Russian Federation)
Description: 150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xolair® (Novartis Pharma AG, Switzerland)
Description: 150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
Study: NCT03112759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
Study: NCT04508504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preop PENG block
Description: Ultrasound-guided injection of 20 mL 0.5% ropivacaine according to the method described by Giron-Arango L in 2018. A needle is inserted at the inguinal level under ultrasound guidance to pass beneath the psoas tendon on top of the iliopubic eminence where the local anesthetic is injected.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo block
Description: Ultrasound-guided placebo injection of 5 mL 0.9% normal saline. Using the same landmarks as for the PENG group, a needle is inserted in the inguinal region under ultrasound guidance, whereby a subcutaneous injection of 5 mL of 0.9% saline is made.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 20 mL 0.5% ropivacaine will be injected for the preop PENG block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 5 mL 0.9% Normal saline will be injected for the Placebo block
Study: NCT01722630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Study: NCT03027258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth
Description: HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant.
Study: NCT02415491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test
Description: MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency.
Study: NCT02967822

Intervention type: GENETIC
Intervention: Biological samples for patients
Description: Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)

Intervention type: GENETIC
Intervention: Biological samples for healthy relatives
Description: Blood samples.
Study: NCT02069379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
Study: NCT02440243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purethal
Description: prerseasonal course of SCIT - three years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Purethal -placebo
Description: preseasonal course of SCIT - three years
Study: NCT02480517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study: NCT04510662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Patients in this group will receive telmisartan 40 mg daily plus standard care.
Study: NCT04144140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7766
Description: E7766, solution, intratumorally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7766
Description: E7766, solution, intratumorally
Study: NCT04465591

Intervention type: DIAGNOSTIC_TEST
Intervention: troponin T fragmentation test
Description: laboratory test from blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: troponin T fragmentation test
Description: laboratory test from blood sample
Study: NCT02844231

Intervention type: OTHER
Group type: OTHER
Intervention: Single-photon emission computed tomography

Intervention type: OTHER
Group type: OTHER
Intervention: Single-photon emission computed tomography
Study: NCT02480517

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ultrasound
Study: NCT02844231

Intervention type: OTHER
Group type: OTHER
Intervention: Single-photon emission computed tomography
Study: NCT00230711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Study: NCT03605277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: 40 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: 40 mg single dose
Study: NCT02069379

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules prepared identically to Metformin capsules
Study: NCT04051515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialysis exercise training
Description: Combined exercise, aerobic and resistance training, implemented by nursing staff

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise training
Description: Combined exercise, aerobic and resistance training, implemented independently home